Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 1 to 20 of 36

1.

Extensive sequence variation in the 3' untranslated region of the KRAS gene in lung and ovarian cancer cases.

Kim M, Chen X, Chin LJ, Paranjape T, Speed WC, Kidd KK, Zhao H, Weidhaas JB, Slack FJ.

Cell Cycle. 2014 Mar 15;13(6):1030-40. doi: 10.4161/cc.27941. Epub 2014 Feb 3.

PMID:
24552817
[PubMed - in process]
2.

Current status and recommendations for the future of research, teaching, and testing in the biological sciences of radiation oncology: report of the American Society for Radiation Oncology Cancer Biology/Radiation Biology Task Force, executive summary.

Wallner PE, Anscher MS, Barker CA, Bassetti M, Bristow RG, Cha YI, Dicker AP, Formenti SC, Graves EE, Hahn SM, Hei TK, Kimmelman AC, Kirsch DG, Kozak KR, Lawrence TS, Marples B, McBride WH, Mikkelsen RB, Park CC, Weidhaas JB, Zietman AL, Steinberg M.

Int J Radiat Oncol Biol Phys. 2014 Jan 1;88(1):11-7. doi: 10.1016/j.ijrobp.2013.09.040. Epub 2013 Nov 15.

PMID:
24246724
[PubMed - indexed for MEDLINE]
3.

SNPs in microRNA binding sites as prognostic and predictive cancer biomarkers.

Preskill C, Weidhaas JB.

Crit Rev Oncog. 2013;18(4):327-40. Review.

PMID:
23614619
[PubMed - indexed for MEDLINE]
4.

SNPing cancer in the bud: microRNA and microRNA-target site polymorphisms as diagnostic and prognostic biomarkers in cancer.

Salzman DW, Weidhaas JB.

Pharmacol Ther. 2013 Jan;137(1):55-63. doi: 10.1016/j.pharmthera.2012.08.016. Epub 2012 Sep 3. Review.

PMID:
22964086
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma.

Babar IA, Cheng CJ, Booth CJ, Liang X, Weidhaas JB, Saltzman WM, Slack FJ.

Proc Natl Acad Sci U S A. 2012 Jun 26;109(26):E1695-704. doi: 10.1073/pnas.1201516109. Epub 2012 Jun 8.

PMID:
22685206
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

A prospective, multicenter study of complementary/alternative medicine (CAM) utilization during definitive radiation for breast cancer.

Moran MS, Ma S, Jagsi R, Yang TJ, Higgins SA, Weidhaas JB, Wilson LD, Lloyd S, Peschel R, Gaudreau B, Rockwell S.

Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):40-6. doi: 10.1016/j.ijrobp.2012.03.025. Epub 2012 Jun 1.

PMID:
22658441
[PubMed - indexed for MEDLINE]
7.

A polymorphism in a let-7 microRNA binding site of KRAS in women with endometriosis.

Grechukhina O, Petracco R, Popkhadze S, Massasa E, Paranjape T, Chan E, Flores I, Weidhaas JB, Taylor HS.

EMBO Mol Med. 2012 Mar;4(3):206-17. doi: 10.1002/emmm.201100200. Epub 2012 Feb 3.

PMID:
22307873
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

KRAS alleles: the LCS6 3'UTR variant and KRAS coding sequence mutations in the NCI-60 panel.

Kundu ST, Nallur S, Paranjape T, Boeke M, Weidhaas JB, Slack FJ.

Cell Cycle. 2012 Jan 15;11(2):361-6. doi: 10.4161/cc.11.2.18794. Epub 2012 Jan 15.

PMID:
22189714
[PubMed - indexed for MEDLINE]
9.

A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.

Ratner ES, Keane FK, Lindner R, Tassi RA, Paranjape T, Glasgow M, Nallur S, Deng Y, Lu L, Steele L, Sand S, Muller RU, Bignotti E, Bellone S, Boeke M, Yao X, Pecorelli S, Ravaggi A, Katsaros D, Zelterman D, Cristea MC, Yu H, Rutherford TJ, Weitzel JN, Neuhausen SL, Schwartz PE, Slack FJ, Santin AD, Weidhaas JB.

Oncogene. 2012 Oct 18;31(42):4559-66. doi: 10.1038/onc.2011.539. Epub 2011 Dec 5.

PMID:
22139083
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Inhibition of hypoxia-induced miR-155 radiosensitizes hypoxic lung cancer cells.

Babar IA, Czochor J, Steinmetz A, Weidhaas JB, Glazer PM, Slack FJ.

Cancer Biol Ther. 2011 Nov 15;12(10):908-14. doi: 10.4161/cbt.12.10.17681. Epub 2011 Nov 15.

PMID:
22027557
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

miRNAs in the spotlight: Making 'silent' mutations speak up.

Salzman DW, Weidhaas JB.

Nat Med. 2011 Aug 4;17(8):934-5. doi: 10.1038/nm0811-934. No abstract available.

PMID:
21818091
[PubMed - indexed for MEDLINE]
12.

MicroRNA signatures differentiate melanoma subtypes.

Chan E, Patel R, Nallur S, Ratner E, Bacchiocchi A, Hoyt K, Szpakowski S, Godshalk S, Ariyan S, Sznol M, Halaban R, Krauthammer M, Tuck D, Slack FJ, Weidhaas JB.

Cell Cycle. 2011 Jun 1;10(11):1845-52. Epub 2011 Jun 1.

PMID:
21543894
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis.

Paranjape T, Heneghan H, Lindner R, Keane FK, Hoffman A, Hollestelle A, Dorairaj J, Geyda K, Pelletier C, Nallur S, Martens JW, Hooning MJ, Kerin M, Zelterman D, Zhu Y, Tuck D, Harris L, Miller N, Slack F, Weidhaas J.

Lancet Oncol. 2011 Apr;12(4):377-86. doi: 10.1016/S1470-2045(11)70044-4. Epub 2011 Mar 22. Erratum in: Lancet Oncol. 2011 Jun;12(6):522.

PMID:
21435948
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice.

Trang P, Wiggins JF, Daige CL, Cho C, Omotola M, Brown D, Weidhaas JB, Bader AG, Slack FJ.

Mol Ther. 2011 Jun;19(6):1116-22. doi: 10.1038/mt.2011.48. Epub 2011 Mar 22.

PMID:
21427705
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Cancer microRNAs: from subtype profiling to predictors of response to therapy.

Chan E, Prado DE, Weidhaas JB.

Trends Mol Med. 2011 May;17(5):235-43. doi: 10.1016/j.molmed.2011.01.008. Epub 2011 Feb 25. Review.

PMID:
21354374
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Rare BRCA1 haplotypes including 3'UTR SNPs associated with breast cancer risk.

Pelletier C, Speed WC, Paranjape T, Keane K, Blitzblau R, Hollestelle A, Safavi K, van den Ouweland A, Zelterman D, Slack FJ, Kidd KK, Weidhaas JB.

Cell Cycle. 2011 Jan 1;10(1):90-9. Epub 2011 Jan 1.

PMID:
21191178
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

A Variant in a MicroRNA complementary site in the 3' UTR of the KIT oncogene increases risk of acral melanoma.

Godshalk SE, Paranjape T, Nallur S, Speed W, Chan E, Molinaro AM, Bacchiocchi A, Hoyt K, Tworkoski K, Stern DF, Sznol M, Ariyan S, Lazova R, Halaban R, Kidd KK, Weidhaas JB, Slack FJ.

Oncogene. 2011 Mar 31;30(13):1542-50. doi: 10.1038/onc.2010.536. Epub 2010 Nov 29.

PMID:
21119596
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

MicroRNA binding site polymorphisms as biomarkers of cancer risk.

Pelletier C, Weidhaas JB.

Expert Rev Mol Diagn. 2010 Sep;10(6):817-29. doi: 10.1586/erm.10.59.

PMID:
20843204
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.

Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, Pelletier C, Blitzblau R, Tassi R, Paranjape T, Hui P, Godwin AK, Yu H, Risch H, Rutherford T, Schwartz P, Santin A, Matloff E, Zelterman D, Slack FJ, Weidhaas JB.

Cancer Res. 2010 Aug 15;70(16):6509-15. doi: 10.1158/0008-5472.CAN-10-0689. Epub 2010 Jul 20.

PMID:
20647319
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

MicroRNA signatures differentiate uterine cancer tumor subtypes.

Ratner ES, Tuck D, Richter C, Nallur S, Patel RM, Schultz V, Hui P, Schwartz PE, Rutherford TJ, Weidhaas JB.

Gynecol Oncol. 2010 Sep;118(3):251-7. doi: 10.1016/j.ygyno.2010.05.010. Epub 2010 Jun 9.

PMID:
20542546
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk